Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd

02566

Company Profile

  • Business description

    Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing, and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, it has built a diversified product portfolio comprising several marketed products, such as Jilifen, Jijufen, Jiouting, Yinuojia, Guyoudao, etc., and has several product candidates under development, such as JY54, JY23, JY47, JY56, JY29-2, etc., targeting various indications. Geographically, the company generates maximum revenue from the Chinese Mainland, and the rest from other countries.

  • Contact

    No. 23, Eighth Street, Baiyang Street
    Qiantang District
    Zhejiang Province
    Hangzhou
    CHN

    T: +86 57186910099

    https://www.china-gene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    1,794

Stocks News & Analysis

stocks

After plunge ASX blue chip undervalued

This company earns a moat from our analysts.
stocks

Older cohorts the budget losers, not necessarily the ASX listed insurers

Proposed legislation removes health insurance rebates.
stocks

Turnaround progressing for ASX share

Margins have rebased by shares are undervalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,829.5017.300.20%
CAC 408,046.6059.110.74%
DAX 4024,614.53306.611.26%
Dow JONES (US)49,686.12159.950.32%
FTSE 10010,387.8364.080.62%
HKSE25,797.85122.670.48%
NASDAQ26,090.73134.41-0.51%
Nikkei 22560,550.59265.36-0.44%
NZX 50 Index12,974.32211.401.66%
S&P 5007,403.050.000.00%
S&P/ASX 2008,604.7023.100.27%
SSE Composite Index4,169.5438.010.92%

Market Movers